[TimAlerts] $VSTM “Dr. Matthew Davids gave an oral presentation of new clinical data from the ongoing Phase Ib/II study evaluating duvelisib in combination with FCR (chemo-immunotherapy) in younger, fit CLL patients,” said Diep Le, MD, PhD, Chief Medical Officer of Verastem Oncology. “The combination regimen achieved an overall response rate (ORR) of 94%, including 26% of patients experiencing a complete response or complete response with incomplete blood count recovery (CR/CRi), and 68% achieving a partial
@MichaelGoode Hey Michael, I'm trying to see which fee structure is better for pennies. Tiered or Fixed (interactive brokers) Have you used both fee structure? If yes which one is best to choose? Thank you in advance.